Disc Medicine to Present at the Virtual 62nd American Society of Hematology Annual Meeting

CAMBRIDGE, Mass., Dec. 2, 2020 /PRNewswire/ — Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, today announced that preclinical data from two pipeline programs that modulate the hepcidin pathway will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition, which will be held virtually December 5-8, 2020.

Details of the presentations are as follows:

Abstract Number: 1690
Title: DISC-a, the First in a Novel Class of Potent and Selective Matriptase-2 Inhibitors for the Treatment of Hematologic Disorders Characterized By Low Hepcidin
Date: Sunday, December 6, 2020, 7:00 AM-3:30 PM EST
Session: 102. Regulation of Iron Metabolism: Poster II
Presenter: Vu Hong, PhD, Director and Project Leader

Abstract Number: 2599
Title: DISC-0974, a Novel, First-in-Class, Anti-Hemojuvelin Monoclonal Antibody Decreases Hepcidin and Increases Transferrin Saturation in a Non-Human Primate Model of Cytokine (IL-6) Induced Hypoferremia
Date: Monday, December 7, 2020, 7:00 AM-3:30 PM EST
Session: 102. Regulation of Iron Metabolism: Poster III
Presenter: Maria Beconi, PhD, SVP of Translational Research and Development

Full abstracts are currently available through the ASH conference website: www.hematology.org/Annual-Meeting/Abstracts/.

About Disc Medicine
Disc Medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases. Currently focused on the hepcidin pathway, the master regulator of iron metabolism, Disc is developing a portfolio of first-in-class therapeutic candidates to transform the treatment of hematologic diseases. For more information, visit www.discmedicine.com.

SOURCE Disc Medicine

Related Links

http://www.discmedicine.com

Source Article

Read more

Disc Medicine to Present at the Piper Sandler 32nd Annual Healthcare Conference

CAMBRIDGE, Mass., Nov. 23, 2020 /PRNewswire/ — Disc Medicine, a hematology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating diseases, announced it will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference.

Disc Medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases. Focused on the hepcidin pathway, the master regulator of iron metabolism, Disc is advancing first-in-class therapies to transform the treatment of hematologic diseases. (PRNewsfoto/Disc Medicine)

A pre-recorded presentation by John Quisel, J.D., Ph.D., Chief Executive Officer of Disc Medicine, will be available beginning on Monday, November 23 at 10:00 am Eastern Standard Time. A link to the presentation will be provided in the “News & Events” section of Disc Medicine’s website at www.discmedicine.com.

About Disc Medicine
Disc Medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases. Currently focused on the hepcidin pathway, the master regulator of iron metabolism, Disc is developing a portfolio of first-in-class therapeutic candidates to transform the treatment of hematologic diseases. For more information, visit www.discmedicine.com.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/disc-medicine-to-present-at-the-piper-sandler-32nd-annual-healthcare-conference-301178870.html

SOURCE Disc Medicine

Source Article

Read more
  • Partner links